(1S)-4-chloroindan-1-ol | 1202577-79-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: (1S)-4-chloroindan-1-ol
• 英文别名: (1S)-4-chloro-2,3-dihydro-1H-inden-1-ol
• CAS: 1202577-79-4
• 化学式: C₉H₉ClO
• mdl: MFCD14705984
• 分子量: 168.623
• InChiKey: IDHGYOQGMVANDO-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (1S)-4-chloroindan-1-ol 、 methyl (3S)-3-ethoxy-3-(4-hydroxyphenyl)propanoate 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 4.0h， 以60%的产率得到methyl (3S)-3-(4-{[(1R)-4-chloro-2,3-dihydro-1H-inden-1-yl]oxy}phenyl)-3-ethoxypropanoate
  参考文献：
  名称：

  Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558

  摘要：

  GPR40 agonists stimulate insulin secretion only under the presence of high glucose concentration. Based on this mechanism, GPR40 agonists are believed to be promising novel insulin secretagogues with low risk of hypoglycemia. The optimizations of 3-aryl-3-ethoxypropanoic acids were performed to improve in vitro activity. We discovered compound 29r (DS-1558), (3S)-3-ethoxy-3-(4-{[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]oxy}phenyl)propanoic acid, which was confirmed to have an enhancing effect on glucose-dependent insulin secretion after intravenous glucose injection in SD rats. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.07.028
• 作为产物：
  描述：

  4-氯-1-茚满酮 在 (1S,2S)-N-p-toluenesulfonyl-1,2-diphenylethylenediamine-ruthenium(mesitylene) 甲酸 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以96%的产率得到(1S)-4-chloroindan-1-ol
  参考文献：
  名称：

  CARBOXYLIC ACID COMPOUND

  摘要：

  寻找具有优异活性和安全性的治疗剂和/或预防剂，用于糖尿病或类似疾病。以下通用式（I）所代表的化合物，或其药理学上可接受的盐。在该式中，X代表 ═C(R5)- 或 ═N—；Y代表 —O— 或 —NH—；L代表键或可替代的C1-C3烷基链；M代表可替代的C3-C10环烷基，可替代的C6-C10芳基，或可替代的杂环基；R1代表C1-C6烷基，C3-C10环烷基，C1-C6卤代烷基，C2-C6烯基，C2-C6炔基，C1-C6脂肪酰基，C1-C6烷氧基C1-C6烷基，或C6-C10芳基；而R2、R3、R4和R5可以相同也可以不同，每个代表氢原子，卤原子，C1-C3烷基，C1-C3卤代烷基，C1-C3烷氧基，或硝基。在这种情况下，R1和R2的烷基基团可以结合在一起形成含有一个氧原子的5-至6-成员杂环环。

  公开号：

  US20110053974A1

文献信息

• [EN] INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS<br/>[FR] ACIDES INDANYLOXYDIHYDROBENZOFURANYLACÉTIQUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012072691A1

  公开（公告）日：2012-06-07

  The present invention relates to compounds defined by formula (I) wherein the variables R1, R2, R3, m, and n are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are activators of the receptor GPR40 and thus are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及具有式(I)定义的化合物，其中变量R1、R2、R3、m和n如权利要求1中定义，具有宝贵的药理活性。特别是，这些化合物是GPR40受体的激动剂，因此适合用于治疗和预防可以通过这种受体影响的疾病，例如代谢性疾病，特别是2型糖尿病。
• NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE
  申请人：Okano Akihiro

  公开号：US20120157459A1

  公开（公告）日：2012-06-21

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where n is 0 to 2; p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is an aryl group which is optionally substituted with L or a heterocyclic group which is optionally substituted with L; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is O, S, —NR 7 —; and R 1 to R 7 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  提供一个以新型化合物作为活性成分的GPR40激活剂，该化合物具有GPR40激动剂作用，该化合物的盐，该盐或化合物的溶剂合物，或者类似物，尤其是胰岛素分泌促进剂以及对糖尿病、肥胖症或其他疾病的预防及/或治疗剂。[解决该问题的方法] 公式(I)的化合物：（其中n为0至2；p为0至4；j为0至3；k为0至2；环A是一个芳基团，可选择性被L取代或是一个杂环团，可选择性被L取代；环B是一个苯环、一个吡啶环或一个嘧啶环；X是O，S，—NR7—；R1至R7是特定基团），该化合物的盐，或该盐或化合物的溶剂合物。
• INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
  申请人：Himmelsbach Frank

  公开号：US20120302566A1

  公开（公告）日：2012-11-29

  The present invention relates to compounds defined by formula (I) wherein the variables R 1 , R 2 , R 3 , m, and n are defined as in claim 1 , possessing valuable pharmacological activity. Particularly, the compounds are activators of the receptor GPR40 and thus are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及由公式(I)定义的化合物 其中变量R1、R2、R3、m和n如权利要求1中定义，具有宝贵的药理活性。特别是，这些化合物是GPR40受体的激动剂，因此适合于治疗和预防可以通过此受体影响的疾病，例如代谢性疾病，特别是2型糖尿病。
• Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist
  作者：Rieko Takano、Masao Yoshida、Masahiro Inoue、Takeshi Honda、Ryutaro Nakashima、Koji Matsumoto、Tatsuya Yano、Tsuneaki Ogata、Nobuaki Watanabe、Masakazu Hirouchi、Tomoko Yoneyama、Shuichiro Ito、Narihiro Toda

  DOI：10.1021/ml500391n

  日期：2015.3.12

  GPR40 is a G protein-coupled receptor that is predominantly expressed in pancreatic beta-cells GPR40 agonists stimulate insulin secretion in the presence of high glucose concentration. On the basis of this mechanism, GPR40 agonists are possible novel insulin secretagogues with reduced or no risk of hypoglycemia. The improvement of in vitro activity and metabolic stability of compound 1 led to the discovery of 13, (3S)-3-ethoxy-3-(4-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1-H-inden-1-yljoxy}phenyl)propanoic acid, as a potent and orally available GPR40 agonist. Compound 13 (DS-1558) was found to have potent glucose lowering effects during an oral glucose tolerance test in ZDF rats.
• Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
  申请人：BOEHRINGER INGELHEIM INTERNATIONAL GMBH

  公开号：EP2646425B1

  公开（公告）日：2015-06-10